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Abstract 
Background 
Oral iron is commonly prescribed to older patients with suspected or confirmed iron deficiency 
anaemia, however few studies have examined the effectiveness of oral iron therapy in the real world 
in this population. We therefore determined the prevalence of iron deficiency in older people 
prescribed oral iron, examined the response mounted to therapy and ascertained predictors of 
response to oral iron. 
Methods 
We analysed a routinely collected, linked dataset from older patients who had undergone inpatient 
rehabilitation between 1999 and 2011. An initial analysis examined patients within this cohort who 
were prescribed iron after rehabilitation and derived three groups based upon their ferritin and 
transferrin indices; probably, possibly and not iron deficient. A second analysis compared pre- and 
post-treatment haemoglobin to determine the degree of response to iron therapy across each 
category of deficiency. Finally, patient demographics, linked biochemistry data and comorbid disease 
based on International Statistical Classification of Disease (ICD-10) codes from previous hospital 
admissions were used in regression modelling to evaluate factors affecting response to therapy.  
Results 
 490 patients were prescribed oral iron within 90 days of rehabilitation discharge. 413/490 (84%) had 
iron indices performed; 94 (23%) were possibly deficient, 224 (54%) were probably deficient, and 95 
(23%) were not deficient. 360/490 patients had both pre and post treatment haemoglobin data and 
iron indices; probably deficient patients mounted a slightly greater response to oral iron (17g/L vs 
12g/L for not deficient; p<0.05). Only pre-treatment haemoglobin, mean cell volume (MCV) and lower 
gastrointestinal pathology were significant predictors of a response to oral iron therapy. Notably, acid-
suppressant use was not a predictor of response.  
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Conclusion 
We conclude that many older patients are exposed to oral iron without good evidence of either iron 
deficiency or a significant response to therapy.  
Key Points  
 Older patients are frequently prescribed oral iron 
 
 Many patients prescribed oral iron lack evidence of iron deficiency and are not monitored 
for response to therapy 
 
 The increase in haemoglobin seen after oral iron supplementation is very modest 
 
 In multivariable analysis, patients with lower gastrointestinal pathology, low mean cell 
volume or low pre-treatment haemoglobin mounted a greater response to oral iron 
supplementation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4 
 
 
 
 
1. Introduction 
Anaemia is common in older populations. The prevalence is approximately 10-15% in those aged 65 
to 85, and can be as high as 26% over the age of 85 [1,2]. The prevalence even within the older age 
group is very variable, given the heterogeneous nature of this cohort and the impact of varying 
patterns of chronic disease, medication use, nutrition and frailty. Anaemia is not only underdiagnosed 
but may also be underestimated as a cause of mortality in this population [3,4]. Iron deficiency 
anaemia is common and may be due to gastrointestinal blood loss, decreased iron absorption [3,5]. 
Causes of bone marrow failure such as myelodysplasia and myeloma become more common with 
increasing age and may account for anaemia in some patients [6,7]. Anaemia of chronic disease due 
to chronic inflammatory disorders [8], and anaemia due to chronic kidney disease are also common 
[2]. Importantly, these various causes of anaemia may coexist in the same patient, leading to 
diagnostic difficulty. In a significant proportion, anaemia may remain unexplained despite appropriate 
investigation [10,11].  
 
Iron deficiency anaemia may be difficult to diagnose in older patients with multiple medical problems 
[4].  Serum ferritin is the most useful blood test to assess iron stores in the absence of inflammation, 
with low serum ferritin confirming iron deficiency [5,12,13]. Ferritin is however an acute phase 
protein, and therefore in patients with concomitant medical problems, a normal ferritin may not fully 
exclude iron deficiency anaemia [8,12]. Hepcidin, a regulatory protein of iron absorption, is generally 
higher in inflammatory states, and this may account for lower availability of serum iron in those with 
anaemia of chronic disease [13] .  
 
Oral iron therapy is prescribed for patients with confirmed iron deficiency or in some cases for 
unexplained anaemia and response to therapy should be monitored by serial measurements of 
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haemoglobin [12]. The failure of anaemia to respond to oral iron therapy may be multifactorial. Iron 
therapy will not be effective for treatment of anaemia if iron stores are replete. If anaemia of chronic 
disease and iron deficiency coexist, iron utilisation may be suboptimal, and no improvement in 
haemoglobin seen. Oral iron therapy, commonly prescribed in the form of ferrous sulphate or ferrous 
fumarate, may cause significant gastrointestinal side effects including diarrhoea, constipation, nausea, 
anorexia and taste disturbance [14].  These may be intolerable leading to poor compliance with the 
prescribed medication, and thus no improvement in anaemia.  
 
Few studies to date have examined the effectiveness of oral iron prescribing in older populations [15]. 
The aims of this study were to ascertain the prevalence of iron prescribing in a cohort of older patients 
discharged from rehabilitation, to examine the response to oral iron therapy in this cohort, and to 
ascertain predictors of response. 
 
2. Methods  
2.1 Analysis Population  
We undertook an analysis of prospectively collected routine clinical data. This analysis used linked 
datasets held by the Health Informatics Centre (HIC) at the University of Dundee. Data on patients 
who had undergone inpatient rehabilitation within the NHS Tayside Medicine for the Elderly Service 
between 1st January 1999 and 31st December 2011 were linked to data on laboratory analyses 
(haematology and biochemistry), hospitalisation episode data include discharge diagnoses, and dates 
of death. Information was accessed through the secure Safe Haven run by HIC which anonymized all 
data prior to hosting on the server for access by the research team. As the analyses used routinely 
collected clinical data, project-specific ethics approval was not required, but approval for use of the 
datasets was obtained from the local Data Protection Officer (Caldicott Guardian).  
 
2.2 Variables  
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Demographic information including sex and age was derived from NHS Tayside records. All 
haematology and biochemistry results, both from hospital and community samples, are stored within 
the HIC SafeHaven system. These included mean cell volume (MCV), haemoglobin at baseline, 
estimated glomerular filtration rate (GFR) (calculated using the MDRD4 equation [16,17]), mean C-
reactive protein (CRP), and serum iron, transferrin, ferritin, vitamin B12 and serum folate, where 
results were available. Baseline haemoglobin was taken as the most recent haemoglobin result 
available prior to the commencement of oral iron therapy. Iron studies comprising ferritin and 
transferrin were used to determine iron status, these were also available through the SafeHaven 
system. Ferritin is primarily used as a marker of iron status in routine UK clinical practice, however 
some studies have demonstrated that serum transferrin can be used to discriminate between iron 
deficiency anaemia and anaemia of chronic disease, hence both were included [18]. Post treatment 
haemoglobin was taken as the highest measurement at any point in the 12 weeks following 
commencement of iron supplementation; given that all data were retrospectively analysed there was 
no set point at which follow up tests had been taken. Anaemia was defined by a starting haemoglobin 
value below the World Health Organisation advised local reference range (120g/L in women and 
130g/L in men) (19). Haematology indices were measured using a Sysmex analyser (Wymbush, Milton 
Keanes, UK); iron and transferrin were measured using a Siemens Advia 2400 analyser, whilst ferritin 
and folate was measured by a Siemens Dimension Vista analyser (Siemens, Surrey, UK). Vitamin B12 
was measured by Siemens Centaur XP (Siemens, Surrey, UK).  
 
Previous hospitalisation with a discharge diagnosis (either as a primary or secondary diagnosis) of 
chronic obstructive pulmonary disease (COPD), myocardial infarction, stroke, heart failure or hip 
fracture were derived from International Statistical Classification of Disease (ICD) 9 and 10 codes taken 
from Scottish Morbidity Record 01 (SMR01) data held by HIC. Any previous cancer diagnosis was 
derived from Scottish Morbidity Record 06 (cancer registry) data. Previous hospitalisation for lower 
gastrointestinal (GI) pathology or upper GI bleeding was recorded by matching with ICD-10 codes, 
which were further categorised in keeping with the work of Button et al.[19]. Previously diagnosed 
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diabetes mellitus was obtained from the Scottish Care Information – Diabetes Cohort (SCI-DC) data 
held by HIC; this dataset records all patients in Scotland with a diagnosis of diabetes [20]. 
 
Data on prescriptions dispensed by community pharmacies and held by HIC were used as source data 
for prescribing; this does not include prescriptions used during hospital stays. We extracted 
prescribing data for aspirin, clopidogrel, anticoagulants, proton pump inhibitors (PPI) and H2 receptor 
blockers. 
 
2.3 Data Analysis  
Analyses were performed using SPSS v21 (IBM, New York, USA). A p value of <0.05 was taken as 
significant for all analyses. The study subpopulation used for the main analyses comprised all patients 
commenced on oral iron therapy at the point of discharge from rehabilitation or within 90 days after 
discharge from rehabilitation. For comparison, the subpopulation who had received iron at any point 
prior to or after admission were also described. Descriptive statistics were generated for each group 
of patients. An initial analysis was carried out to determine the prevalence of iron deficiency in 
accordance with the categorization into three groups. Patients were split into these three groups 
based upon their ferritin and transferrin indices; not deficient (transferrin <2.0g/L, ferritin >100ug/L), 
possibly deficient (transferrin 2.0-2.5g/L, ferritin 50-100ug/L) and probably deficient (transferrin 
>2.5g/L, ferritin <50ug/L) [8]. In each category only transferrin or ferritin was required, given that most 
patients only had one of these indices measured. Where results from transferrin or ferritin would 
place patients in different groups, the most iron-deficient group was preferred.  
 
A second analysis examined the response to oral iron therapy mounted by each of the above groups 
of patients. A significant response was considered to be at least a 20g/L increase in haemoglobin; such 
a response is typically seen within 3 weeks of commencing iron therapy in younger patients with iron 
deficiency anaemia [12,21,22].  This cut off was used to divide patients into responders and non-
responders. Candidate factors were then tested for their association with response vs non-response 
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using binary logistic regression model testing (forced entry). A further analysis was conducted using a 
linear regression model to test the association of baseline factors with the magnitude of response to 
iron therapy. 
 
Finally, based upon their response to treatment the patient cohort was then split into two groups; 
responders and non-responders. These groups were then compared in order to determine factors 
which may influence response to oral iron therapy, including background demographics (age and sex) 
as well as concurrent disease according to ICD-10. Variables against which analyses were carried out 
are shown in Table 1.  
 
3. Results 
3.1 Patient eligibility and iron status  
4382 patients were initially identified for their involvement with the inpatient rehabilitation service. 
Of this cohort, 490 were prescribed iron within 90 days following of discharge from rehabilitation, and 
thus were eligible for the main analyses. 360/490 patients (73%) of these patients had at least one 
follow up haemoglobin measurement within 90 days of initiation of iron therapy, hence were suitable 
for inclusion in the final analyses of response to treatment. A flowchart demonstrating patient 
selection for each phase of the analysis is depicted in Figure 1. 
 
413/490 (84%) of patients had recorded iron studies (ferritin and transferrin) to allow for 
determination of iron status with 94 (23%) possibly deficient, 224 (54%) probably deficient and 95 
(23%) not deficient. Of the 360 patients with pre and post treatment haemoglobin data and iron 
indices, 70 (19%) were possibly deficient, 173 (48%) were probably deficient and 117 (33%) were not 
iron deficient.  
 
Vitamin B12 and folate deficiency were also considered as part of the analysis, primarily to rule out 
this as a cause of anaemia. Deficiency was classed as <160ng/L for B12; only 16/490 patients 
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prescribed iron were vitamin B12 deficient. For folate, deficiency was classed as <3.1ug/L; 23/490 
patients had folate deficiency. 
 
3.2 Effect of baseline iron status on response to iron therapy 
Haemoglobin results both pre and post iron treatment were available for 360 patients, allowing for 
investigation of response to therapy. These patients were then subdivided by pre-treatment iron 
status for further analysis. Table 2 shows the haemoglobin increase mounted by each of the four 
groups; not deficient, possibly deficient, probably deficient and those without iron studies.  
 
3.3 Predictors of response to iron therapy 
A third analysis examined the association between baseline variables and response to iron therapy. 
For the purpose of this analysis patients were defined as responders (n=116, with haemoglobin 
increase >20g/L) and non-responders (n=244, with haemoglobin increase <20g/L) based upon 
biochemical markers within 90 days of treatment starting. Table 3 shows univariate associations 
between baseline variables and response to iron therapy. A binary logistic regression model was used 
to determine the significance of factors affecting responders and non-responders to oral iron therapy. 
This showed that only pre-treatment haemoglobin, MCV and presence of lower GI pathology were 
significant predictors of a response to oral iron therapy (i.e. >20g/L rise in haemoglobin). 
 
 
3.4 Predictive value of MCV for response to iron therapy 
Given the strength of association between MCV and response to iron therapy, a receiver-operator 
characteristic curve was constructed; the c-statistic for the ROC curve was 0.71 (95% CI 0.65 to 0.77). 
MCV had limited utility for identifying a group of patients unlikely to respond to oral iron however; 
33/116 (28%) of responders had a baseline MCV of >90fl (normal range 85-95fl). All results were based 
on the samples tested from the same analyser.  
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4. Discussion 
This study aimed to examine the response to oral iron therapy and determinants of this response. As 
such, the primary inclusion criteria hinged upon prescription of iron supplementation; hence most, 
but not all of the included patients were anaemic according to local haematology reference ranges. 
Our results show that many older patients are prescribed oral iron without evidence of iron deficiency. 
Not all patients receiving oral iron had iron studies performed, and of those that did have iron studies, 
a quarter had no evidence of iron deficiency prior to commencing iron therapy. Many patients also 
lacked follow up haemoglobin measurement to test whether iron therapy was effective; of those with 
follow-up haemoglobin levels, only a third showed a rise of >20g/L in haemoglobin taken by this study 
to denote a response. 
 
Many patients in this analysis had only a mildly reduced haemoglobin; baseline haemoglobin and MCV 
were the most powerful predictors of a successful response to iron therapy. It is perhaps unsurprising 
that those with a lower initial haemoglobin mount the most significant response to iron; this is in 
keeping with previous findings [23] that responders to oral iron therapy had a lower baseline 
haemoglobin (91 vs 98 g/L). Additionally, these patients tended to be younger and had a lower Body 
Mass Index (BMI) (27.9 vs 31.1kg/m2). Whilst age was not a determinant of response to iron therapy 
in our study, it is likely that in older patients age is less of a discriminant than comorbidities or 
performance status compared to a younger population.  
 
Interestingly, C-reactive protein was not a significant factor in the response patients mounted to oral 
iron therapy, with no appreciable difference between responders and non-responders. However, this 
study only took into account conventional CRP measurements, and hence it is possible that chronic 
low grade inflammation could play a role. High-sensitivity CRP assays would be required to confirm or 
deny this hypothesis, but as these assays were not used in routine clinical practice, such analyses 
cannot be undertaken with the current dataset.  
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Crucially, those who were biochemically iron deficient were more likely to respond to oral iron therapy 
compared to those who did not show laboratory evidence of iron deficiency. This emphasises the 
importance of identifying a cause of anaemia, particularly in older patients; iron therapy will not 
improve anaemia in those who are not iron deficient.  
 
Diagnosing iron deficiency based on widely available measures of iron metabolism, such as serum iron, 
transferrin and ferritin, is not straightforward. The gold standard test for assessment of iron status is 
a bone marrow biopsy, however this is invasive and therefore not usually appropriate, especially in 
elderly patients. Thus, biochemical markers are often relied upon as a surrogate [24]. We used a 
graded approach to classifying iron status, in part based on published guidance from the British Society 
for Haematology [22]. Despite the use of this classification, less than half of those in the ‘probable iron 
deficiency’ group showed a 20g/L rise in haemoglobin. As previously discussed, there are several 
possible contributors to this poor response rate including poor compliance with prescribed iron 
therapy, absence of true iron deficiency and the presence of chronic inflammatory processes. 
 
 Previous studies noted that MCV and traditional iron studies are an unreliable test of true iron 
deficiency anaemia when used in older populations [4,25,26]. One study found that up to 22% of 
elderly patients without biochemical evidence of iron deficiency would still respond to oral iron 
therapy [25]; a similar proportion to the response rate in the ‘not iron deficient’ group in our study. 
Some of this response may however be due to intermittent gastrointestinal bleeding that resolves and 
allows Hb to rise, rather than a true response to iron therapy. Of note, in our study, MCV was 
significant in determining response to iron and hence it may be appropriate to prescribe a therapeutic 
trial of oral iron on the basis of microcytic anaemia in the absence of iron studies, with monitoring of 
haemoglobin to determine response.  
 
A systemic review and meta-analysis carried out by Tay & Soiza [27] found similarly that older patients 
mounted only a weak response to oral iron therapy. Two of the three studies included in their analysis 
 12 
showed a mean increase in haemoglobin of only 4g/L and 6g/L, neither reaching statistical 
significance. More importantly, there was no statistically significant improvement in mortality, length 
of hospital stay or quality of life. Interestingly, the same study hypothesised that poor absorption of 
iron supplements due to concurrent atrophic gastritis and PPI use maybe a factor in poor response in 
older patients. Our findings do not support this hypothesis, as there was no significant difference 
between the responders and non-responders despite 65% and 53% respectively taking PPIs. 
Conversely, the lack of difference in PPI use rates between the groups does not support PPIs being an 
effective strategy to ameliorate blood loss and hence improve response to oral iron in this group – 
this may be because of the wide range of pathologies causing iron deficiency in older people, many of 
which would not be improved by acid suppression. 
 
A further reason for lack of response to oral iron may be ongoing blood loss, emphasising the need to 
investigate and treat the underlying cause of the anaemia; patients with recognised lower GI 
pathology were more likely to respond to iron, suggesting that finding and treating the cause of the 
anaemia is an important part of ensuring a response to therapy. However, many older, frail patients 
are either unable or unwilling to undergo invasive investigation for the cause of iron deficiency [28]. 
Simple tests, such as searching for concomitant vitamin deficiencies can still be performed in the 
frailest of patients and may improve the response to oral iron; as well as proving or disproving iron 
deficiency as the principle cause of anaemia. In Tayside a recent addition to the general practice test 
repertoire is the ‘anaemia screen’ blood test. On receipt of these samples, a full blood count is first 
performed and if anaemia is found, further tests, for example blood film and ferritin, or vitamin B12 
and folate in the case of macrocytic anaemia are cascaded. This test sequence reduces the need for 
further blood sampling and provides the GP promptly with increased diagnostic information. This may 
help reduce iron prescribing for those who are not iron deficient, as information about iron status is 
readily available.  A re-audit of data following the introduction of this test would be useful in order to 
determine exact outcomes.  
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Strengths of our study include the use of routinely collected data, which ensures that our results 
reflect real life practice with minimal selection of patients. The use of linked diagnostic, prescribing 
and lab data enhanced the range of variables that we were able to consider. A number of weaknesses 
should also be noted. This study focussed on those admitted to a rehabilitation service in a single 
health board area and hence investigated at a population of patients with significant burden of 
disease. Whilst it was possible to correct for several common comorbidities and their effect on 
response to oral iron, it was impossible to encompass all pathologies and treatments thereof. The 
heterogeneous nature of this cohort of patients complicates the analysis to a degree, however this 
heterogeneity reflects ‘real-world’ clinical practice - older patients rarely present with isolated 
pathologies. 
 
Once of the major limitations of this study was in the classification of iron deficiency and degrees 
thereof, given that guidelines vary for the population under study. In the absence of a clear consensus, 
iron indices were set assuming that chronic inflammation and renal impairment were likely to be 
common in our population, thus higher thresholds for ferritin were appropriate such as those 
recommended in other guidelines [11,29,30] . Interpretation of transferrin levels is similarly lacking in 
consensus, but we selected a level below the normal range (2-4g/L) as indicating that anaemia of 
chronic disease was a more likely diagnosis than iron-deficiency anaemia; conversely, the higher the 
transferrin level, the more likely iron-deficiency becomes, and the choice of a 2.5g/L cut off reflects a 
level consistent with clinical practice by geriatricians. 
 
Our basis for defining a significant response to iron was based on an improvement in haemoglobin; 
for many patients these follow up data was not available and for others we classified their response 
as non-significant as their haemoglobin did not rise by 20g/L. However, we could not take account of 
symptomatic improvement from a small increase in haemoglobin, and we do not of course know 
whether haemoglobin would have fallen further in the absence of iron therapy. Despite having access 
to prescribing data, we were unable to ascertain adherence to therapy as the number of times per 
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day that iron was recommended was not well captured in the datasets that we used. Similarly, the 
data set limited our ability to exclude all causes of anaemia such as haematuria, poor nutrition or 
uterine bleeding. The availability of such data as well as previous endoscopy results would have 
enhanced our analysis; without this we have relied upon ICD-10 codes for upper and lower GI 
pathologies and bleeds as a surrogate for one of the most common sources of blood loss, as well as 
influencing possible dietary malabsorption.  
 
5. Conclusion  
Oral iron therapy is commonly used in older patients, but in many cases investigation for iron 
deficiency, accurate diagnosis of iron deficiency, and monitoring of response to therapy are 
inadequate. These factors may help to explain the poor response rate to oral iron, suggesting that 
many older people are exposed to potential side effects and harms of oral iron for no symptomatic 
gain. Better systems are required to improve investigation, diagnosis, and monitoring of anaemia in 
older people, and consideration should be given to stopping therapy or using alternatives to oral iron 
if no response to therapy is seen. 
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Figure 1 Flow diagram depicting selection of patients 
 
 
 
 
 
  
n=4,382 Patients in rehabilitation 
n=1,466 Patients prescribed iron at any 
time
n=490 Patients prescribed iron within 
90 days of discharge from rehabilitation 
n=360 Patients with post-treatment 
haemoglobin data 
 20 
Table 1. Baseline patient details 
 Whole cohort (n=4382) Ever prescribed iron 
(n=1466) 
Prescribed iron 
within 90 days of 
rehabilitation 
discharge (n=490) 
Prescribed iron within 90 days 
of rehabilitation discharge 
with follow up, haemoglobin 
results available (n=360) 
Mean age (yrs) (SD) 83.9 (7.6) 85.2 (7.0) 85.6 (7.1) 85.2 (6.7) 
Male sex (%) 1351 (31) 463 (32) 148 (30) 107 (30) 
Congestive heart failure (%) 386 (9) 165 (11) 38 (8) 29 (8) 
Previous stroke (%) 312 (7) 110 (8) 32 (7) 28 (8) 
Chronic obstructive pulmonary disease (COPD) (%) 635 (15) 198 (14) 65 (13) 49 (14) 
Previous myocardial infarction (%) 755 (17) 333 (23) 80 (16) 66 (18) 
Diabetes mellitus (%) 753 (17) 282 (19) 83 (17) 59 (16) 
Previous cancer diagnosis (%) 564 (13) 193 (13) 56 (11) 43 (12) 
Previous hip fracture (%) 491 (12) 180 (12) 51 (10) 34 (9) 
Previous admission for upper gastrointestinal bleed (%) - 26 (2) 26 (5) 19 (5) 
Evidence of lower gastrointestinal pathology (%) - 92 (6) 90 (18) 68 (19) 
Died during rehabilitation admission (%) 373 (8.5) 88 (6) 0 (0) 0 (0) 
Mean admission Barthel score (SD) 10.3 (3.8) 10.7 (3.7) 11.2 (3.6) 11.3 (3.7) 
Mean discharge Barthel score (SD) 14.3 (4.7) 15.0 (4.3) 15.7 (3.6) 15.9 (3.6) 
Discharged to own home (%) 3002 (69) 1081 (74) 399 (81) 299 (83) 
Mean eGFR (ml/min/1.73m2) (SD) 63 (27) 50 (12) 50 (12) 50  (12) 
eGFR <45ml/min/1.73m2 (%) 1061 (24) 450 (31) 151 (31) 110 (31) 
Mean haemoglobin (g/L) (SD) 120 (19) 105 (15) 105 (15) 109 (13) 
Anaemia (female Hb<120; male Hb<130g/L) (%) 2521 (58) 1057 (72) 432 (88) 320 (89) 
On proton pump inhibitor (%) - 268 (18) 265 (58) 204 (57) 
On histamine 2 receptor antagonist (%) - 40 (3) 40 (8) 24 (7) 
On aspirin (%) - 218 (15) 215 (44) 157 (44) 
On clopidogrel (%) - 37 (3) 37 (8) 29 (8) 
On oral anticoagulants (%) - 47 (3) 47 (10) 37 (10) 
All values are those at the point of discharge from the first rehabilitation admission 
eGFR: estimated Glomerular Filtration Rate 
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Table 2. Haemoglobin response to iron therapy in relation to iron status (n=360) 
 
Group No. with 
haemoglobin 
measured 
Mean baseline 
haemoglobin 
(g/L) (SD) 
Anaemia at 
baseline (%)** 
Mean baseline 
mean cell 
volume (fl) (SD) 
No (%) with 
haemoglobin 
increase >20g/L 
Mean 
haemoglobin 
increase (g/L) 
(SD) 
Mean ferritin 
(ug/L) (SD)  
Not iron 
deficient 
59 104 (1.3) 53 (90) 94 (10) 14 (24)  12 (1.5) 347.8 
Possibly iron 
deficient 
70 103 (1.4) 62 (89) 91 (7) 17 (24) 13 (1.5) 166.5 
Probably iron 
deficient 
173 104 (1.7) 152 (88) 87 (9) 67 (39)* 17 (1.6)* 51.1 
No iron studies  58 104 (1.7) 53 (91) 88 (8) 18 (31) 13 (1.5) - 
 
*p<0.05 ** Hb<120g/L for females or <130g/L for males 
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Table 3 . Factors associated with response vs non-response to oral iron therapy (n=360) 
 
 Univariate analysis Binary logistic regressiona 
 Responders 
(n=116) 
Non-responders 
(n=244) 
p Odds ratio (95% CI)  p 
eGFR <45ml/min/1.73m2 (%) 38 (33) 70 (29) 0.53 -   
Mean mean cell volume (SD)b 84.6 (9.5) 90.9 (8.1) <0.001 0.93 (0.90-0.96) -0.074 <0.001 
Mean start haemoglobin (g/L) (SD) 96 (1.6) 108 (1.4) <0.001 0.66 (0.54-0.79) -0.419 <0.001 
Vitamin B12 <160ng/L (%)c 5 (4) 11 (5) 0.91 - - - 
Folate <3.1ug/L (%)c 3 (3) 9 (4) 0.64 - - - 
Mean C-reactive protein (mg/L) (SD)d 44 (54) 47 (69) 0.71 - - - 
Aspirin (%) 49 (42) 108 (44) 0.73 -   
Clopidogrel (%)  6 (5) 23 (9) 0.17 0.44 (0.15-1.28) -0.823 0.13 
Oral anticoagulant (%)  12 (10) 25 (10) 0.98 -   
Proton pump inhibitor (%) 75 (65) 129 (53) 0.04 1.47 (0.87-2.48) 0.384 0.15 
H2 receptor antagonist (%) 9 (8) 15 (6) 0.57 -   
Upper gastrointestinal bleed admission (%) 9 (8) 10 (4) 0.15 2.24 (0.81-6.16) 0.806 0.12 
Lower gastrointestinal pathology (%) 30 (26) 38 (16) 0.02 1.76 (0.94-3.30) 0.568 0.08 
Diabetes mellitus (%) 25 (22) 34 (14) 0.07 1.34 (0.97-1.86) 0.293 0.08 
COPD (%) 18 (16) 31 (13) 0.47 - - - 
Previous myocardial infarction (%) 18 (16) 48 (20) 0.34 - - - 
Previous stroke (%) 6 (5) 22 (9) 0.20 0.48 (0.17-1.41) -0.729 0.18 
Congestive heart failure (%) 7 (6) 22 (9) 0.33 - - - 
Mean discharge Barthel score (SD) 15.8 (3.5) 16.0 (3.6) 0.63 - - - 
 
a Variables selected if p ≤ 0.2 on univariate analysis (forced entry model) 
b Mean cell volume normal range 85-96fl  
c 92 responders and 191 non-responders had vitamin B12 and folate measurements recorded  
d C-reactive protein levels were available for 313 patients 
 
 
